Design considerations for early-phase clinical trials of immune-oncology agents

BACKGROUND: With numerous and fast approvals of different agents including immune checkpoint inhibitors, monoclonal antibodies, or chimeric antigen receptor (CAR) T-cell therapy, immunotherapy is now an established form of cancer treatment. These agents have demonstrated impressive clinical activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Wages, Nolan A., Chiuzan, Cody, Panageas, Katherine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103998/
https://www.ncbi.nlm.nih.gov/pubmed/30134959
http://dx.doi.org/10.1186/s40425-018-0389-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103998/
https://www.ncbi.nlm.nih.gov/pubmed/30134959
http://dx.doi.org/10.1186/s40425-018-0389-8

Ejemplares similares